ARBOR VITA CORPORATION

Study Results Using Onco*E6*™ Oral and Cervical Tests Presented at the International Papillomavirus Conference

Fremont, California [August 25, 2014] – Arbor Vita Corporation, a privately held company, announced today results presented at the 29th International Papillomavirus (IPV) Conference based on the groundbreaking Onco***E6***™ proteomic-based diagnostics platform applied to diverse clinical settings. Presentations were given by Charite University Hospital in Berlin, Catholic Hospital Battor (Ghana), the German Cancer Research Center, and Arbor Vita Corporation.

One clinical setting is cervical cancer screening. Although current cervical cancer screening technologies such as Pap smears and HPV tests have been effective in reducing cervical cancer rates in the United States and Europe, they require costly infrastructure to perform and suffer in specificity. These limitations in cost (millions in equipment with highly trained personnel) and specificity (too many false positives requiring more testing) have made cervical cancer screening impractical in many parts of the world where cervical cancer is the number one or two cause of death in women. This is tragic because when this cancer is detected early, treatment is simple and effective.

Researchers from the Charite University Hospital in Berlin reported that Onco***E6***™ Cervical Test was able to detect cervical cancers and precancers with equal efficacy using patient-collected specimens compared to physician collected samples. These findings opened up the possibility of broad field testing not possible before. Their collaborators at the Catholic Hospital in Battor, in the Volta Region of Ghana reported on efforts currently under way to screen women in remote parts of Ghana. Women in the villages collect their own cervical/vaginal samples and are tested on site (possible with the Onco***E6***™ Cervical Test). Because Onco***E6***™ Cervical Test has the fewest false positive results of any cervical cancer screening technology, a positive finding can be treated in the field. The combination of self collected specimen, point of care testing and high accuracy will permit a "screen and treatment" strategy to enable cervical cancer screening and treatment to become available to women anywhere in the world.

Onco***E6***™ also can detect HPV caused oral cancer. Michael Douglas (movie star) recently caused a big uproar when he attributed his oral cancer (diagnosed in 2010) to HPV. This revelation highlights that oral cancers are on the rise, in part from a rise in HPV infection despite a decline in traditional risk factors like alcohol and tobacco consumption. Currently, there is no easy way to distinguish between oral cancers caused by HPV versus those that are not, an important distinction because treatment is different. Investigators from the German Cancer Research Center reported that the Onco***E6***™ Oral Test can easily and accurately determine which oral cancers are caused by HPV in a single step without extensive, invasive and expensive work up.

Arbor Vita reported exciting new products in development to address unmet medical needs world-wide including a new generation of Onco***E6***™ Cervical Test with expanded HPV type coverage.

The Onco***E6***™ Cervical Test carries the European Union CE Marking of quality and is available in many parts of the world. The Onco***E6***™ Oral Test is available for research purposes. For more information, please contact: info@arborvita.com

About Arbor Vita Corporation
Founded in 1998, Arbor Vita Corporation is a privately held biotechnology company located in Fremont, California, focusing on the discovery, development, and commercialization of novel proteomic-based diagnostics and therapeutics. The company's proprietary PDZ protein technology continues to produce groundbreaking solutions to complex health challenges, including infectious diseases and cancer.
www.arborvita.com

48371 Fremont Blvd, Suite 101, Fremont, CA 94538 U.S.A.
P: 408.585.3900 • F: 408.585.3901 • www.arborvita.com